{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:19:17Z","timestamp":1782512357675,"version":"3.54.5"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>We have recently demonstrated that genetic inactivation of EWSR1 :\u2009: FLI1 by CRISPR\/Cas9, successfully blocks cell proliferation in a cell model of Ewing sarcoma. However, CRISPR\/Cas9-mediated gene editing can exhibit off-target effects, and thus, precise regulation of Cas9 expression in target cells is essential to develop gene-editing strategies to inactivate EWSR1 :\u2009: FLI1 in Ewing sarcoma cells. In this study, we demonstrate that Cas9 can be specifically expressed in Ewing sarcoma cells when located downstream a promoter consisting of GGAA repeats and a consensus TATA box (GGAAprom). Under these conditions, Cas9 is selectively expressed in Ewing sarcoma cells that express EWSR1 :\u2009: FLI1 oncoproteins, but not in cells expressing wild-type FLI1. Consequently, Ewing sarcoma cells infected with GGAAprom&gt;Cas9 and a specific gRNA designed to inactivate EWSR1 :\u2009: FLI1, showed successful EWSR1 :\u2009: FLI1 inactivation and the subsequent blockade of cell proliferation. Notably, GGAAprom&gt;Cas9 can be efficiently delivered to Ewing sarcoma cells via adenoviral vectors both in vitro and in vivo, highlighting the potential of this approach for Ewing sarcoma treatment. Our results demonstrate that the CRISPR\/Cas9 machinery is safe and specific for Ewing sarcoma cells when driven under a GGAAprom, paving the way for the development of cancer gene therapies based on the selective expression of genes with therapeutic potential.<\/jats:p>","DOI":"10.1038\/s41417-025-00887-8","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T15:38:01Z","timestamp":1742053081000},"page":"437-449","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Targeted inactivation of EWSR1 :\u2009: FLI1 gene in Ewing sarcoma via CRISPR\/Cas9 driven by an Ewing-specific GGAA promoter"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8837-5346","authenticated-orcid":false,"given":"Saint T.","family":"Cervera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2950-3931","authenticated-orcid":false,"given":"Selene","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5643-739X","authenticated-orcid":false,"given":"Mar\u00eda","family":"Iranzo-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8940-1916","authenticated-orcid":false,"given":"Laura","family":"Notario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel M.","family":"Melero-Fern\u00e1ndez de Mera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6287-8391","authenticated-orcid":false,"given":"Javier","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"key":"887_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-4026-8","volume":"21","author":"J Anderton","year":"2020","unstructured":"Anderton J, Moroz V, Marec-Berard P, Gaspar N, Laurence V, Martin-Broto J, et al. International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol. Trials 2020;21:96.","journal-title":"Trials"},{"key":"887_CR2","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S0140-6736(22)01790-1","volume":"400","author":"B Brennan","year":"2022","unstructured":"Brennan B, Kirton L, Marec-Berard P, Gaspar N, Laurence V, Martin-Broto J, et al. Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial. Lancet 2022;400:1513\u201321.","journal-title":"Lancet"},{"key":"887_CR3","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","volume":"33","author":"N Gaspar","year":"2015","unstructured":"Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC, et al. Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. J Clin Oncol : J Am Soc Clin Oncol. 2015;33:3036\u201346.","journal-title":"J Clin Oncol : J Am Soc Clin Oncol"},{"key":"887_CR4","doi-asserted-by":"publisher","first-page":"8613","DOI":"10.18632\/oncotarget.6937","volume":"7","author":"H Kovar","year":"2016","unstructured":"Kovar H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, et al. The second European interdisciplinary Ewing sarcoma research summit-A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget 2016;7:8613\u201324.","journal-title":"Oncotarget"},{"key":"887_CR5","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1002\/cam4.3712","volume":"10","author":"A Felix","year":"2021","unstructured":"Felix A, Berlanga P, Toulmonde M, Landman-Parker J, Dumont S, Vassal G, et al. Systematic review of phase-I\/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research. Cancer Med. 2021;10:1589\u2013604.","journal-title":"Cancer Med"},{"key":"887_CR6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/359162a0","volume":"359","author":"O Delattre","year":"1992","unstructured":"Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162\u20135.","journal-title":"Nature"},{"key":"887_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-018-0003-x","volume":"4","author":"TGP Grunewald","year":"2018","unstructured":"Grunewald TGP, Cidre-Aranaz F, Surdez D, Tomazou EM, de Alava E, Kovar H, et al. Ewing sarcoma. Nat Rev Dis Prim. 2018;4:5.","journal-title":"Nat Rev Dis Prim"},{"key":"887_CR8","doi-asserted-by":"publisher","first-page":"8853","DOI":"10.1093\/nar\/gkt678","volume":"41","author":"G Stoll","year":"2013","unstructured":"Stoll G, Surdez D, Tirode F, Laud K, Barillot E, Zinovyev A, et al. Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis. Nucleic Acids Res. 2013;41:8853\u201371.","journal-title":"Nucleic Acids Res"},{"key":"887_CR9","doi-asserted-by":"publisher","first-page":"6034","DOI":"10.1038\/onc.2008.203","volume":"27","author":"E Garcia-Aragoncillo","year":"2008","unstructured":"Garcia-Aragoncillo E, Carrillo J, Lalli E, Agra N, Gomez-Lopez G, Pestana A, et al. DAX1, a direct target of EWS\/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing\u2019s tumor cells. Oncogene 2008;27:6034\u201343.","journal-title":"Oncogene"},{"key":"887_CR10","doi-asserted-by":"crossref","unstructured":"Garcia-Garcia L, Fernandez-Tabanera E, Cervera ST, Melero-Fernandez de Mera RM, Josa S, Gonzalez-Gonzalez L, et al. The Transcription Factor FEZF1, a Direct Target of EWSR1-FLI1 in Ewing Sarcoma Cells, Regulates the Expression of Neural-Specific Genes. Cancers. 2021;13:5668.","DOI":"10.3390\/cancers13225668"},{"key":"887_CR11","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.1073\/pnas.0810759106","volume":"106","author":"GH Richter","year":"2009","unstructured":"Richter GH, Plehm S, Fasan A, Rossler S, Unland R, Bennani-Baiti IM, et al. EZH2 is a mediator of EWS\/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci USA. 2009;106:5324\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"887_CR12","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/nm.4273","volume":"23","author":"NC Sheffield","year":"2017","unstructured":"Sheffield NC, Pierron G, Klughammer J, Datlinger P, Schonegger A, Schuster M, et al. DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. Nat Med. 2017;23:386\u201395.","journal-title":"Nat Med"},{"key":"887_CR13","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.celrep.2015.01.042","volume":"10","author":"EM Tomazou","year":"2015","unstructured":"Tomazou EM, Sheffield NC, Schmidl C, Schuster M, Schonegger A, Datlinger P, et al. Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1. Cell Rep. 2015;10:1082\u201395.","journal-title":"Cell Rep."},{"key":"887_CR14","doi-asserted-by":"publisher","first-page":"8984","DOI":"10.1158\/0008-5472.CAN-05-0565","volume":"65","author":"S Hu-Lieskovan","year":"2005","unstructured":"Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing\u2019s sarcoma. Cancer Res. 2005;65:8984\u201392.","journal-title":"Cancer Res"},{"key":"887_CR15","doi-asserted-by":"publisher","first-page":"7275","DOI":"10.1128\/MCB.24.16.7275-7283.2004","volume":"24","author":"A Prieur","year":"2004","unstructured":"Prieur A, Tirode F, Cohen P, Delattre O. EWS\/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol. 2004;24:7275\u201383.","journal-title":"Mol Cell Biol"},{"key":"887_CR16","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1517\/14728222.2014.947963","volume":"18","author":"H Kovar","year":"2014","unstructured":"Kovar H. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS\/FLI-1 fusion in Ewing sarcoma as novel therapy. Expert Opin Ther Targets. 2014;18:1315\u201328.","journal-title":"Expert Opin Ther Targets"},{"key":"887_CR17","doi-asserted-by":"crossref","unstructured":"Cervera ST, Rodriguez-Martin C, Fernandez-Tabanera E, Melero-Fernandez de Mera RM, Morin M, Fernandez-Penalver S, et al. Therapeutic Potential of EWSR1-FLI1 Inactivation by CRISPR\/Cas9 in Ewing Sarcoma. Cancers. 2021;13:3783.","DOI":"10.3390\/cancers13153783"},{"key":"887_CR18","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s12033-022-00550-9","volume":"65","author":"S Maity","year":"2023","unstructured":"Maity S, Mukherjee R, Banerjee S. Recent Advances and Therapeutic Strategies Using CRISPR Genome Editing Technique for the Treatment of Cancer. Mol Biotechnol. 2023;65:206\u201326.","journal-title":"Mol Biotechnol"},{"key":"887_CR19","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/s41417-023-00597-z","volume":"30","author":"SE Ahmadi","year":"2023","unstructured":"Ahmadi SE, Soleymani M, Shahriyary F, Amirzargar MR, Ofoghi M, Fattahi MD, et al. Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR\/Cas-mediated cancer therapy. Cancer Gene Ther. 2023;30:936\u201354.","journal-title":"Cancer Gene Ther"},{"key":"887_CR20","first-page":"281","volume":"16","author":"H Yin","year":"2019","unstructured":"Yin H, Xue W, Anderson DG. CRISPR-Cas: a tool for cancer research and therapeutics. Nature reviews. Clin Oncol. 2019;16:281\u201395.","journal-title":"Clin Oncol"},{"key":"887_CR21","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/ijc.21578","volume":"118","author":"M Mendiola","year":"2006","unstructured":"Mendiola M, Carrillo J, Garcia E, Lalli E, Hernandez T, de Alava E, et al. The orphan nuclear receptor DAX1 is up-regulated by the EWS\/FLI1 oncoprotein and is highly expressed in Ewing tumors. Int J Cancer. 2006;118:1381\u20139.","journal-title":"Int J Cancer"},{"key":"887_CR22","first-page":"1561","volume":"10","author":"KT Tamai","year":"1996","unstructured":"Tamai KT, Monaco L, Alastalo TP, Lalli E, Parvinen M, Sassone-Corsi P. Hormonal and developmental regulation of DAX-1 expression in Sertoli cells. Mol Endocrinol. 1996;10:1561\u20139.","journal-title":"Mol Endocrinol"},{"key":"887_CR23","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41587-019-0032-3","volume":"37","author":"K Clement","year":"2019","unstructured":"Clement K, Rees H, Canver MC, Gehrke JM, Farouni R, Hsu JY, et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat Biotechnol. 2019;37:224\u20136.","journal-title":"Nat Biotechnol"},{"key":"887_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.","journal-title":"Sci Rep."},{"key":"887_CR25","doi-asserted-by":"crossref","unstructured":"Fernandez-Tabanera E, Garcia-Garcia L, Rodriguez-Martin C, Cervera ST, Gonzalez-Gonzalez L, Robledo C, et al. CD44 Modulates Cell Migration and Invasion in Ewing Sarcoma Cells. Int J Mol Sci. 2023;24:11774.","DOI":"10.3390\/ijms241411774"},{"key":"887_CR26","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00280-015-2726-7","volume":"75","author":"R Tancredi","year":"2015","unstructured":"Tancredi R, Zambelli A, DaPrada GA, Fregoni V, Pavesi L, Riccardi A, et al. Targeting the EWS-FLI1 transcription factor in Ewing sarcoma. Cancer Chemother Pharmacol. 2015;75:1317\u201320.","journal-title":"Cancer Chemother Pharmacol"},{"key":"887_CR27","doi-asserted-by":"publisher","first-page":"6657","DOI":"10.1158\/0008-5472.CAN-16-0568","volume":"76","author":"ML Harlow","year":"2016","unstructured":"Harlow ML, Maloney N, Roland J, Guillen Navarro MJ, Easton MK, Kitchen-Goosen SM, et al. Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus. Cancer Res. 2016;76:6657\u201368.","journal-title":"Cancer Res"},{"key":"887_CR28","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/jnci\/djr156","volume":"103","author":"PJ Grohar","year":"2011","unstructured":"Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen Q-R, Yeung C, et al. Identification of an Inhibitor of the EWS-FLI1 Oncogenic Transcription Factor by High-Throughput Screening. JNCI: J Natl Cancer Inst. 2011;103:962\u201378.","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"887_CR29","first-page":"4105","volume":"22","author":"CL Osgood","year":"2016","unstructured":"Osgood CL, Maloney N, Kidd CG, Kitchen-Goosen S, Segars L, Gebregiorgis M, et al. Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor. Clinical cancer research : an official journal of the American Association for. Cancer Res. 2016;22:4105\u201318.","journal-title":"Cancer Res"},{"key":"887_CR30","doi-asserted-by":"publisher","first-page":"172","DOI":"10.18632\/oncotarget.454","volume":"3","author":"JS Barber-Rotenberg","year":"2012","unstructured":"Barber-Rotenberg JS, Selvanathan SP, Kong Y, Erkizan HV, Snyder TM, Hong SP, et al. Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1. Oncotarget 2012;3:172\u201382.","journal-title":"Oncotarget"},{"key":"887_CR31","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nm.1983","volume":"15","author":"HV Erkizan","year":"2009","unstructured":"Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing\u2019s sarcoma. Nat Med. 2009;15:750\u20136.","journal-title":"Nat Med"},{"key":"887_CR32","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00280-017-3382-x","volume":"80","author":"PJ Grohar","year":"2017","unstructured":"Grohar PJ, Glod J, Peer CJ, Sissung TM, Arnaldez FI, Long L, et al. A phase I\/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript. Cancer Chemother Pharmacol. 2017;80:645\u201352.","journal-title":"Cancer Chemother Pharmacol"},{"key":"887_CR33","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2217\/14796694.1.4.521","volume":"1","author":"A Uren","year":"2005","unstructured":"Uren A, Toretsky JA. Ewing\u2019s sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent. Future Oncol. 2005;1:521\u20138.","journal-title":"Future Oncol"},{"key":"887_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-021-01462-5","volume":"38","author":"P Singh","year":"2021","unstructured":"Singh P, Kumar V, Gupta SK, Kumari G, Verma M. Combating TKI resistance in CML by inhibiting the PI3K\/Akt\/mTOR pathway in combination with TKIs: a review. Med Oncol. 2021;38:10.","journal-title":"Med Oncol"},{"key":"887_CR35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s11899-019-00543-7","volume":"14","author":"M Yaghmaie","year":"2019","unstructured":"Yaghmaie M, Yeung CC. Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors. Curr Hematol Malig Rep. 2019;14:395\u2013404.","journal-title":"Curr Hematol Malig Rep."},{"key":"887_CR36","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/neuonc\/noy202","volume":"21","author":"MW Kieran","year":"2019","unstructured":"Kieran MW, Goumnerova L, Manley P, Chi SN, Marcus KJ, Manzanera AG, et al. Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. Neuro Oncol. 2019;21:537\u201346.","journal-title":"Neuro Oncol"},{"key":"887_CR37","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.ymthe.2020.11.001","volume":"29","author":"JD Predina","year":"2021","unstructured":"Predina JD, Haas AR, Martinez M, O\u2019Brien S, Moon EK, Woodruff P, et al. Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity. Mol Ther : J Am Soc Gene Ther. 2021;29:658\u201370.","journal-title":"Mol Ther : J Am Soc Gene Ther"},{"key":"887_CR38","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3892\/mco.2015.519","volume":"3","author":"M Kubo","year":"2015","unstructured":"Kubo M, Satoh T, Tabata KI, Tsumura H, Iwamura M, Baba S, et al. Enhanced central memory cluster of differentiation 8(+) and tumor antigen-specific T cells in prostate cancer patients receiving repeated in situ adenovirus-mediated suicide gene therapy. Mol Clin Oncol. 2015;3:515\u201321.","journal-title":"Mol Clin Oncol"},{"key":"887_CR39","doi-asserted-by":"crossref","unstructured":"Atasheva S, Emerson CC, Yao J, Young C, Stewart PL, Shayakhmetov DM. Systemic cancer therapy with engineered adenovirus that evades innate immunity. Sci Transl Med. 2020;12:6659.","DOI":"10.1126\/scitranslmed.abc6659"},{"key":"887_CR40","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.xphs.2019.10.003","volume":"109","author":"A Mehta","year":"2020","unstructured":"Mehta A, Merkel OM. Immunogenicity of Cas9 Protein. J Pharm Sci. 2020;109:62\u20137.","journal-title":"J Pharm Sci"},{"key":"887_CR41","doi-asserted-by":"publisher","first-page":"1138596","DOI":"10.3389\/fbioe.2023.1138596","volume":"11","author":"R Ewaisha","year":"2023","unstructured":"Ewaisha R, Anderson KS. Immunogenicity of CRISPR therapeutics-Critical considerations for clinical translation. Front Bioeng Biotechnol. 2023;11:1138596.","journal-title":"Front Bioeng Biotechnol."},{"key":"887_CR42","doi-asserted-by":"crossref","unstructured":"Evdokimova V, Gassmann H, Radvanyi L, Burdach SEG. Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma. Cancers. 2022;15:272.","DOI":"10.3390\/cancers15010272"},{"key":"887_CR43","first-page":"4968","volume":"28","author":"AR Cillo","year":"2022","unstructured":"Cillo AR, Mukherjee E, Bailey NG, Onkar S, Daley J, Salgado C, et al. Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks. Clinical cancer research : an official journal of the American Association for. Cancer Res2022;28:4968\u201382.","journal-title":"Cancer Res"},{"key":"887_CR44","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1158\/2767-9764.CRC-23-0027","volume":"3","author":"LL Visser","year":"2023","unstructured":"Visser LL, Bleijs M, Margaritis T, van de Wetering M, Holstege FCP, Clevers H. Ewing Sarcoma Single-cell Transcriptome Analysis Reveals Functionally Impaired Antigen-presenting Cells. Cancer Res Commun 2023;3:2158\u201369.","journal-title":"Cancer Res Commun"},{"key":"887_CR45","doi-asserted-by":"publisher","first-page":"1277987.","DOI":"10.3389\/fimmu.2023.1277987","volume":"14","author":"W Luo","year":"2023","unstructured":"Luo W, Hoang H, Liao Y, Pan J, Ayello J, Cairo MS. A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma. Front Immunol. 2023;14:1277987.","journal-title":"Front Immunol"},{"key":"887_CR46","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","volume":"20","author":"J Chuprin","year":"2023","unstructured":"Chuprin J, Buettner H, Seedhom MO, Greiner DL, Keck JG, Ishikawa F, et al. Humanized mouse models for immuno-oncology research. Nat Rev Clin Oncol. 2023;20:192\u2013206.","journal-title":"Nat Rev Clin Oncol"},{"key":"887_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01641-6","volume":"21","author":"TLB Holting","year":"2022","unstructured":"Holting TLB, Cidre-Aranaz F, Matzek D, Popper B, Jacobi SJ, Funk CM, et al. Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood sarcoma. Mol Cancer. 2022;21:199.","journal-title":"Mol Cancer"},{"key":"887_CR48","doi-asserted-by":"crossref","unstructured":"Scarsella L, Ehrke-Schulz E, Paulussen M, Thal SC, Ehrhardt A, Aydin M. Advances of Recombinant Adenoviral Vectors in Preclinical and Clinical Applications. Viruses. 2024;16:377.","DOI":"10.3390\/v16030377"},{"key":"887_CR49","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1089\/hum.2022.228","volume":"34","author":"Y Sheldon","year":"2023","unstructured":"Sheldon Y, Yoo BC, Kmiec E, Petrelli N, Tiesi G, Warner S. Review of Safety Data for Adenovirus 5 as a Delivery Vector for Intratumoral Cancer Gene Therapy. Hum Gene Ther. 2023;34:314\u201324.","journal-title":"Hum Gene Ther"},{"key":"887_CR50","doi-asserted-by":"publisher","first-page":"12267","DOI":"10.1002\/jcp.27972","volume":"234","author":"A Karimian","year":"2019","unstructured":"Karimian A, Azizian K, Parsian H, Rafieian S, Shafiei-Irannejad V, Kheyrollah M, et al. CRISPR\/Cas9 technology as a potent molecular tool for gene therapy. J Cell Physiol. 2019;234:12267\u201377.","journal-title":"J Cell Physiol"},{"key":"887_CR51","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41371-020-0378-5","volume":"35","author":"D Sekar","year":"2021","unstructured":"Sekar D, Lakshmanan, G MB. Implications of CRISPR\/Cas9 system in Hypertension and its related diseases. J Hum Hypertens. 2021;35:642\u20134.","journal-title":"J Hum Hypertens"},{"key":"887_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01565-1","volume":"21","author":"SC Selvakumar","year":"2022","unstructured":"Selvakumar SC, Preethi KA, Ross K, Tusubira D, Khan MWA, Mani P, et al. CRISPR\/Cas9 and next generation sequencing in the personalized treatment of Cancer. Mol cancer. 2022;21:83.","journal-title":"Mol cancer"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00887-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00887-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00887-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T12:04:09Z","timestamp":1744027449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00887-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["887"],"URL":"https:\/\/doi.org\/10.1038\/s41417-025-00887-8","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Experiments with animals were performed according to Animal Welfare guidelines and were approved by the Animal Experimentation Ethics Committee of the Instituto de Salud Carlos III (CBA 25_2020 and CBA 24_2022) and the Agriculture Department of the Madrid Region (PROEX 253.8\/20 and PROEX 302.3\/22).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}